WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 558295
CAS#: 195156-77-5 (stearate)
Description: Valomaciclovir stearate (A-174606.0; ABT-606; EPB-348; MIV-606; RP-606) is a DNA polymerase inhibitor potentially for treatment of acute herpes zoster and EB virus infection. Valomaciclovir stearate is an orally available and a prodrug of Valomaciclovir with broad-spectrum antiviral activity against a variety of important herpesviruses, including Epstein-Barr virus, or EBV (the first virus to be directly associated with human cancer), varicella zoster virus, or herpes zoster (cause of shingles), and herpes simplex virus 1 and 2.
MedKoo Cat#: 558295
Name: Valomaciclovir stearate
CAS#: 195156-77-5 (stearate)
Chemical Formula: C33H58N6O5
Exact Mass: 618.4469
Molecular Weight: 618.864
Elemental Analysis: C, 64.05; H, 9.45; N, 13.58; O, 12.93
Related CAS #: 195156-77-5 (stearate) 195157-39-2 (HCl) 195156-78-6 (TFA) 195157-34-7
Synonym: Valomaciclovir stearate; A-174606.0; A 174606.0; A174606.0; ABT-606; ABT 606; ABT606; EPB-348; EPB348; EPB 348; MIV-606; MIV 606; MIV606; RP-606; RP606; RP 606;
IUPAC/Chemical Name: (R)-4-((L-valyl)oxy)-2-((2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl)butyl stearate
InChi Key: ACBSZTQIFTYFGH-IAPPQJPRSA-N
InChi Code: InChI=1S/C33H58N6O5/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-27(40)44-23-26(20-21-43-32(42)28(34)25(2)3)22-39-24-36-29-30(39)37-33(35)38-31(29)41/h24-26,28H,4-23,34H2,1-3H3,(H3,35,37,38,41)/t26-,28+/m1/s1
SMILES Code: N[C@@H](C(C)C)C(OCC[C@H](CN1C=NC2=C1N=C(N)NC2=O)COC(CCCCCCCCCCCCCCCCC)=O)=O
Appearance: White to off-white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | Valomaciclovir stearate (A-174606.0; ABT-606; EPB-348; MIV-606; RP-606) is a DNA polymerase inhibitor. |
| In vitro activity: | TBD |
| In vivo activity: | TBD |
The following data is based on the product molecular weight 618.864 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | TBD |
| In vitro protocol: | TBD |
| In vivo protocol: | TBD |
1: Andrei G, Snoeck R. Advances and Perspectives in the Management of Varicella- Zoster Virus Infections. Molecules. 2021 Feb 20;26(4):1132. doi: 10.3390/molecules26041132. PMID: 33672709; PMCID: PMC7924330.
2: Krecmerova M. Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals. Mini Rev Med Chem. 2017;17(10):818-833. doi: 10.2174/1389557517666170216151601. PMID: 28215138.
3: El Hayderi L, Rübben A, Nikkels AF. Alpha-Herpesviridae in der Dermatologie : Herpes-simplex-Virus Typ I und II [The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II. German version]. Hautarzt. 2017 Mar;68(3):181-186. German. doi: 10.1007/s00105-016-3929-5. PMID: 28197699.
4: El Hayderi L, Rübben A, Nikkels AF. The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II. Hautarzt. 2017 Dec;68(Suppl 1):1-5. English. doi: 10.1007/s00105-016-3919-7. PMID: 28197698.
5: De Paor M, O'Brien K, Fahey T, Smith SM. Antiviral agents for infectious mononucleosis (glandular fever). Cochrane Database Syst Rev. 2016 Dec 8;12(12):CD011487. doi: 10.1002/14651858.CD011487.pub2. PMID: 27933614; PMCID: PMC6463965.
6: De SK, Hart JC, Breuer J. Herpes simplex virus and varicella zoster virus: recent advances in therapy. Curr Opin Infect Dis. 2015 Dec;28(6):589-95. doi: 10.1097/QCO.0000000000000211. PMID: 26524331.
7: Andrei G, Snoeck R. Advances in the treatment of varicella-zoster virus infections. Adv Pharmacol. 2013;67:107-68. doi: 10.1016/B978-0-12-405880-4.00004-4. PMID: 23886000.
8: Tyring SK, Plunkett S, Scribner AR, Broker RE, Herrod JN, Handke LT, Wise JM, Martin PA; Valomaciclovir Zoster Study Group. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial. J Med Virol. 2012 Aug;84(8):1224-32. doi: 10.1002/jmv.23329. PMID: 22711350.
9: Price NB, Prichard MN. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol. 2011 Dec;1(6):548-54. doi: 10.1016/j.coviro.2011.10.015. PMID: 22162744; PMCID: PMC3230035.
10: Andrei G, Snoeck R. Emerging drugs for varicella-zoster virus infections. Expert Opin Emerg Drugs. 2011 Sep;16(3):507-35. doi: 10.1517/14728214.2011.591786. Epub 2011 Jun 24. PMID: 21699441.
Note:
CAS#195157-34-7 (Valomaciclovir)
